A detailed history of Citigroup Inc transactions in Exelixis, Inc. stock. As of the latest transaction made, Citigroup Inc holds 586,228 shares of EXEL stock, worth $19.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
586,228
Previous 209,464 179.87%
Holding current value
$19.8 Million
Previous $4.71 Million 223.25%
% of portfolio
0.01%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$21.96 - $27.6 $8.27 Million - $10.4 Million
376,764 Added 179.87%
586,228 $15.2 Million
Q2 2024

Aug 12, 2024

SELL
$20.34 - $23.73 $4.38 Million - $5.11 Million
-215,441 Reduced 50.7%
209,464 $4.71 Million
Q1 2024

May 10, 2024

BUY
$20.17 - $23.93 $4.28 Million - $5.07 Million
211,996 Added 99.57%
424,905 $10.1 Million
Q4 2023

Feb 09, 2024

SELL
$19.25 - $24.13 $284,341 - $356,424
-14,771 Reduced 6.49%
212,909 $5.11 Million
Q3 2023

Nov 09, 2023

BUY
$19.04 - $22.74 $637,287 - $761,130
33,471 Added 17.23%
227,680 $4.97 Million
Q2 2023

Aug 10, 2023

SELL
$18.17 - $20.48 $3.54 Million - $3.99 Million
-195,038 Reduced 50.11%
194,209 $3.71 Million
Q1 2023

May 11, 2023

BUY
$16.3 - $19.41 $1.49 Million - $1.77 Million
91,186 Added 30.59%
389,247 $7.56 Million
Q4 2022

Feb 09, 2023

SELL
$14.96 - $17.39 $2.49 Million - $2.89 Million
-166,411 Reduced 35.83%
298,061 $4.78 Million
Q3 2022

Nov 10, 2022

BUY
$15.68 - $22.27 $2.82 Million - $4 Million
179,643 Added 63.07%
464,472 $7.28 Million
Q2 2022

Aug 10, 2022

BUY
$17.44 - $23.16 $2.98 Million - $3.96 Million
171,040 Added 150.31%
284,829 $5.93 Million
Q1 2022

May 12, 2022

SELL
$17.03 - $22.67 $3.12 Million - $4.15 Million
-183,130 Reduced 61.68%
113,789 $2.58 Million
Q4 2021

Feb 10, 2022

BUY
$15.84 - $21.88 $2.18 Million - $3.01 Million
137,655 Added 86.43%
296,919 $5.43 Million
Q3 2021

Nov 10, 2021

BUY
$16.3 - $21.14 $2.6 Million - $3.37 Million
159,264 New
159,264 $3.37 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.9B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.